Keywords
Genetic mutations
Targeted therapy
Immunotherapy
Submitted : 2022-04-20
Accepted : 2022-05-05
Published : 2022-05-20
Abstract
Melanoma is a tumor caused by the deterioration of melanocytes. Both genetic factors and environmental factors contribute to the occurrence of the disease. Melanoma accounts for about 1% to 3% of all malignant tumors, and its prevalence is increasing year by year at the rate of 3% to 5%. With the exception of early surgical resection, there is a lack of specific treatment for patients with melanoma, and many of them have poor prognosis. Treatment strategies for advanced melanoma have been developing rapidly in recent years. Many new therapeutic drugs have emerged and are being tested in recent years. This review focuses on the current development of melanoma treatment (specifically, gene targeted therapy and immunotherapy) and discusses future treatment possibilities.
References
Czirbesz K, Gorka E, Balatoni T, et al., 2019, Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data. Pathol Oncol Res, 25(1): 45-50.
Koelblinger P, Thuerigen O, Dummer R, 2018, Development of Encorafenib for BRAF-Mutated Advanced Melanoma. Current Opinion in Oncology, 30(2): 125-133.
Larkin J, Ascierto PA, Dreno B, et al., 2014, Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. New England Journal of Medicine, 371(20): 1867-1876.
Ascierto PA, Dummer R, Gogas HJ, et al., 2020, Update on Tolerability and Overall Survival in COLUMBUS: Landmark Analysis of a Randomised Phase 3 Trial of Encorafenib Plus Binimetinib Vs Vemurafenib or Encorafenib in Patients with BRAF V600-Mutant Melanoma. Eur J Cancer, 126: 33-44.
Zeng H, Liu F, Zhou H, et al., 2021, Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?. Frontiers in Oncology, 11: 775100.
Carvajal RD, Antonescu CR, Wolchok JD, et al., 2011, KIT as a Therapeutic Target in Metastatic Melanoma. Jama, 305(22): 2327-2334.
Kalinsky K, Lee S, Rubin KM, et al., 2017, A Phase 2 Trial of Dasatinib in Patients with Locally Advanced or Stage IV Mucosal, Acral, or Vulvovaginal Melanoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer, 123(14): 2688-2697.
Camacho LH, 2015, CTLA-4 Blockade with Ipilimumab: Biology, Safety, Efficacy, and Future Considerations. Cancer Medicine, 4(5): 661-672.
Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al., 2016, Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. The New England Journal of Medicine, 375(19): 1845-1855.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al., 2017, Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 377(14): 1345-1356.
Hamid O, Robert C, Daud A, et al., 2019, Five-Year Survival Outcomes for Patients with Advanced Melanoma Treated with Pembrolizumab in KEYNOTE-001. Ann Oncol, 30(4): 582-588.
Long G, Dummer R, Flaherty K, et al., 2015, Abstract B16: NEMO: A Phase 3 Trial of Binimetinib (MEK162) Versus Dacarbazine in Patients with Advanced NRAS-Mutant Melanoma Who Are Untreated or Have Progressed on or After Immunotherapy. Cancer Research, 75(14 Supplement): B16.
Li Y, Zhong C, Wang J, et al., 2021, NOL7 Facilitates Melanoma Progression and Metastasis. Signal Transduction and Targeted Therapy, 6(1): 352.